Ultrasound-guided biopsy for osteolytic lesions of the appendicular skeleton without extra-osseous component
Skeletal Radiology · 17.11.2026
DOI: 10.1007/s00256-026-05444-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Skeletal Radiology, online erschienen am 17.11.2026. Verfasst von George Aurelian Toader und 5 weiteren Autor:innen. Beteiligte Einrichtung: Diagnostic and Interventional Radiology, IRCCS Istituto Ortopedico Rizzoli, Via GC Pupilli 1, 40136, Bologna, Italy. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Objective
US-guided biopsy is currently used for soft-tissue tumors or bone tumors with extra-skeletal extension. Percutaneous CT-guided biopsy is the current standard for diagnosing bone lesions, but has significant drawbacks, including radiation exposure, lack of real-time needle evaluation, and limited assessment of intralesional vascularity. We aimed to assess the diagnostic yield and feasibility of ultrasound guidance, with CT-guided biopsies as reference, in osteolytic appendicular bone lesions with cortical thinning or disruption but without an extra-osseous component. Materials and methods Retrospective analysis of 100 consecutive patients with osteolytic or mixed-pattern appendicular lesions with cortical thinning or disruption and no extra-osseous component, biopsied at a tertiary orthopedic center between November 2022 and July 2026: 22 under ultrasound guidance and 78 under CT guidance. Diagnostic yield, needle caliber, complications, and radiation dose were evaluated.
Results
The cohorts did not differ significantly in demographics or lesion size and depth, whereas anatomical site distribution differed ( p = 0.02). The diagnostic yield for ultrasound-guided procedures was 90.9% ( n = 20/22; 95% CI: 70.8–98.9%), compared to 75.6% ( n = 59/78; 95% CI: 64.4–84.9%) for the CT-guided group ( p = 0.15). Needle caliber was significantly smaller in the ultrasound-guided group (predominantly 14 G versus 8 G; p < 0.001). No complications were recorded in the investigational group, with one mild vasovagal reaction among CT controls. Median Dose Length Product in the CT cohort was 141 mGy*cm (IQR, 69–292).
Conclusion
Our preliminary experience suggests that ultrasound-guided biopsy may represent a feasible complementary approach to CT guidance in selected osteolytic (or mixed) appendicular bone lesions with cortical involvement even without an extra-osseous extension.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Diagnostic and Interventional Radiology, IRCCS Istituto Ortopedico Rizzoli, Via GC Pupilli 1, 40136, Bologna, Italy.
- Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138, Bologna, Italy.
- Department of Orthopaedic Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136, Bologna, Italy.
- Radiology Department, Unidade Local de Saúde Algarve, Hospital de Faro, 8000-386, Faro, Portugal.
- Department of Diagnostic and Interventional Radiology, Ospedale Santo Spirito, Azienda Sanitaria Locale Di Alessandria, 15033, Alessandria, Italy.
- Diagnostic and Interventional Radiology, IRCCS Istituto Ortopedico Rizzoli, Via GC Pupilli 1, 40136, Bologna, Italy. paolo.spinnato1982@gmail.com.
Zitieren
APA
Toader, G. A., Ponti, F., Errani, C., Gonçalves, M., Romeo, D., & Spinnato, P. (2026). Ultrasound-guided biopsy for osteolytic lesions of the appendicular skeleton without extra-osseous component. Skeletal Radiology. https://doi.org/10.1007/s00256-026-05444-4
Vancouver
Toader GA, Ponti F, Errani C, Gonçalves M, Romeo D, Spinnato P. Ultrasound-guided biopsy for osteolytic lesions of the appendicular skeleton without extra-osseous component. Skeletal Radiology. 2026. doi:10.1007/s00256-026-05444-4
BibTeX
@article{Toader2026,
author = {Toader, George Aurelian and Ponti, Federico and Errani, Costantino and Gonçalves, Matilde and Romeo, Domenico and Spinnato, Paolo},
title = {Ultrasound-guided biopsy for osteolytic lesions of the appendicular skeleton without extra-osseous component},
journal = {Skeletal Radiology},
year = {2026},
doi = {10.1007/s00256-026-05444-4}
}
EUVIMED